4 unknown, 2 recruiting, 1 active not recruiting. 5 Phase 1, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Unknown 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Unknown 2, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Relapsed Adult ALL: new trials by email Literature Review of Relapsed Adult ALL trials Research Report on Relapsed Adult ALL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia Senl_B19 autologous CAR-T (S1904) treatment - Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia | Not applicable | Recruiting | Peking University People's Hospital | 130 | 2024-10-01 | 2025-03-12 |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Plerixafor - Relapsed Adult ALL, Relapsed Adult AML | Phase 2 | Unknown | The First Hospital of Jilin University | 28 | 2023-09-01 | 2023-11-21 |
| ThisCART19A Bridging to alloHSCT for R/R B-ALL Treatment - CAR, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2022-12-01 | 2023-01-11 |
| Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) autologous CD19-directed chimeric antigen receptor (CAR) T-cells - Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL | Phase 1 / Phase 2 | Recruiting | University of Alberta | 63 | 2021-03-03 | 2026-02-09 |
| Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT anti-CD19 allo-CAR-T cells - Relapsed Adult ALL, B Cell Leukemia | Phase 1 | Unknown | Xinqiao Hospital of Chongqing | 18 | 2020-11-20 | 2020-11-17 |
| CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) CD19.CAR-aNKT cells - Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 13 | 2020-04-14 | 2026-07-13 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) GLIDE - Hematologic Cancer, Relapse Leukemia | Phase 1 / Phase 2 | Unknown | Ciusss de L'Est de l'Île de Montréal | 20 | 2017-02-06 | 2017-12-06 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Lymphoma, Non-Hodgkin (3) · Leukemia, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Lymphoma, B-Cell (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Leukemia (7) · Leukemia, Lymphoid (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma (4) · Leukemia, Myeloid (2) · Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Cardiovascular Diseases (1)
Therapeutics (2) · Automobiles (1) · plerixafor (1)
Baylor College of Medicine (1) · Ciusss de L'Est de l'Île de Montréal (1) · Peking University People's Hospital (1) · The First Affiliated Hospital of Soochow University (1) · The First Hospital of Jilin University (1) · University of Alberta (1) · Xinqiao Hospital of Chongqing (1)
China (4) · Canada (2) · United States (1)
Carlos Ramos, MD (1) · Denis-Claude Roy, MD PhD (1) · Dr. Michael P Chu, MD (1) · He Huang, MD (1) · Long Su, PhD (1) · Silvy Lachance, MD (1) · Xi Zhang, MD phD (1)
P50CA126752 (1)